Bulaquine  (Synonyms: CDRI 80/53; Elubaquine)

Bulaquine (CDRI 80/53) is a potent antimalarial agent which is an analogue of Primaquine (HY-12651A). Bulaquine affects multiple metabolism pathways and shows inhibition effect on Plasmodium cynomolgi infection. Bulaquine can be used for the research of malaria^[1][2][3].

Bulaquine (40 mg/kg; p.o. once) affects multiple pathways in vivo^[1].
Bulaquine (1.25 mg/kg; once daily; for 7 days) shows 100% curative anti-relapse activity with a primaquine index of 0.8 for rhesus monkeys with Plasmodium cynomolgi B infection^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

369.46

C₂₁H₂₇N₃O₃

79781-00-3

C/C(NCCCC(NC1=CC(OC)=CC2=C1N=CC=C2)C)=C3C(OCC/3)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Noel S, et al. Identification of differentially expressed genes after acute exposure to bulaquine (CDRI 80/53) in mice liver. Basic Clin Pharmacol Toxicol. 2008 Dec;103(6):522-9.  [Content Brief]

  [2]. Dutta GP, et al. Radical curative activity of a new 8-aminoquinoline derivative (CDRI 80/53) against Plasmodium cynomolgi B in monkeys. Am J Trop Med Hyg. 1989 Dec;41(6):635-7.  [Content Brief]

  [3]. Wells TN, et al. Targeting the hypnozoite reservoir of Plasmodium vivax: the hidden obstacle to malaria elimination. Trends Parasitol. 2010 Mar;26(3):145-51.Wells TN, et al. Targeting the hypnozoite reservoir of Plasmodium vivax: the hidden obstacle to malaria elimination. Trends Parasitol. 2010 Mar;26(3):145-51.  [Content Brief]